# IN VITRO METABOLISM AND NON-CLINICAL ADME STUDIES IDIQ CONTRACT. POP 9/27/21-9/26/26. NTE $3.5 MILLION.  FIRST TASK ORDER 01 OBLIGATED IN THE AMOUNT O

> **NIH NIH N01** · SRI INTERNATIONAL · 2021 · $89,708

## Abstract

The objective of this contract is to carry out in vitro metabolism and permeability and in vivo ADME studies to support the medications development program of the National Institute on Drug Abuse (NIDA). NIDA and NIDA sponsored investigators will use the data obtained for submissions to the Food and Drug Administration (FDA) in support of Investigational New Drugs (INDs) and New Drug Applications (NDAs).

## Key facts

- **NIH application ID:** 10505766
- **Project number:** 75N95021D00025-0-9999-1
- **Recipient organization:** SRI INTERNATIONAL
- **Principal Investigator:** MARY BASTIDA
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $89,708
- **Award type:** —
- **Project period:** 2021-09-27 → 2026-09-26

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10505766

## Citation

> US National Institutes of Health, RePORTER application 10505766, IN VITRO METABOLISM AND NON-CLINICAL ADME STUDIES IDIQ CONTRACT. POP 9/27/21-9/26/26. NTE $3.5 MILLION.  FIRST TASK ORDER 01 OBLIGATED IN THE AMOUNT O (75N95021D00025-0-9999-1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10505766. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*